Mindfulness-assisted Psychedelic Therapy (MAPT)
This randomised, open-label, parallel arm trial (n=40) will examine the potential synergy between psilocybin (25 mg, single dose) and 8 weeks of mindfulness training versus psilocybin alone in healthy adults.
Details
A pilot randomised open-label parallel trial in healthy adults (N=40) comparing a single oral 25 mg dose of psilocybin combined with an 8-week mindfulness training course versus psilocybin alone to evaluate feasibility and preliminary efficacy.
Assessments include questionnaires, computerized cognitive tests, and EEG at baseline and post-treatment, with brief follow-ups at 8 weeks and 1 year. Primary feasibility outcome is retention at 8 weeks; secondary outcomes include mood, inflammatory and neurotrophic markers, EEG measures, and safety (AEs).
Results will inform larger trials in clinical populations and future grant applications.